The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model

Background: The farnesoid X receptor (FXR) influences hepatic metabolism, inflammation and liver fibrosis as key components of non-alcoholic steatohepatitis (NASH). We studied the effects of the non-steroidal FXR agonist cilofexor (formerly GS-9674) on portal pressure and fibrosis in experimental NA...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwabl, Philipp, Hambruch, Eva, Budas, Grant R., Supper, Paul, Burnet, Michael, Liles, John T., Birkel, Manfred, Brusilovskaya, Ksenia, Königshofer, Philipp, Peck-Radosavljevic, Markus, Watkins, William J., Trauner, Michael, Breckenridge, David G., Kremoser, Claus, Reiberger, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827357/
https://www.ncbi.nlm.nih.gov/pubmed/33435509
http://dx.doi.org/10.3390/biomedicines9010060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827357/
https://www.ncbi.nlm.nih.gov/pubmed/33435509
http://dx.doi.org/10.3390/biomedicines9010060

Ejemplares similares